Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
暂无分享,去创建一个
G. Everson | M. Sulkowski | J. McHutchison | I. Jacobson | S. Gordon | John G. McHutchison | J. Alam | Gregory T. Everson | Ira M. Jacobson | Andrew J. Muir | Mark Sulkowski | A. Muir | Stuart C. Gordon | Lindsay McNair | John Alam | Robert Kauffman | R. Kauffman | L. Mcnair
[1] H. T. Head,et al. Global surveillance and control of hepatitis C , 1999 .
[2] J. Pawlotsky,et al. The hepatitis C virus life cycle as a target for new antiviral therapies. , 2007, Gastroenterology.
[3] Tara L. Kieffer,et al. Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.
[4] D. Lavanchy,et al. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. , 1999, Journal of viral hepatitis.
[5] William M. Lee,et al. 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY , 2008 .
[6] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[7] Tara L. Kieffer,et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.
[8] G. Gores,et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. , 2003 .
[9] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[10] Jean-Michel Pawlotsky,et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.
[11] M. Manns,et al. The way forward in HCV treatment — finding the right path , 2007, Nature Reviews Drug Discovery.
[12] J. McHutchison,et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. , 2008, Journal of hepatology.
[13] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[14] G. Gores,et al. Hepatitis C–related hepatocellular carcinoma in the United States: influence of ethnic status , 2003, American Journal of Gastroenterology.
[15] Thomas T. Pace. California Pacific Medical Center , 1992 .
[16] P. Kwo,et al. Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial , 2007, Hepatology.
[17] J. McHutchison,et al. American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.
[18] Tara L. Kieffer,et al. Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.
[19] P. Killenberg,et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.
[20] S. Zeuzem,et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.
[21] A. Kwong,et al. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.